The healing stack expands on the popular Wolverine stack (BPC-157 + TB-500) by adding GHK-Cu, a copper-binding peptide with published human data in wound healing and tissue remodeling. The result is a three-pathway approach to tissue repair: BPC-157 for angiogenesis and intracellular repair signaling, TB-500 for cell migration via actin upregulation, and GHK-Cu for extracellular matrix remodeling and immune cell recruitment.
The addition of GHK-Cu addresses a gap in the Wolverine stack — neither BPC-157 nor TB-500 has strong evidence for extracellular matrix (ECM) remodeling, which is critical for proper tissue architecture restoration. GHK-Cu activates metalloproteinases that break down damaged ECM and stimulates synthesis of new collagen and glycosaminoglycans. It also has published human study support, which is a significant evidence advantage.
Important: No clinical trial has studied this three-peptide combination. BPC-157 and TB-500 are research compounds under FDA reclassification review. GHK-Cu is available in consumer skincare products (topical) but injectable use is off-label. This guide is for educational purposes only and does not constitute medical advice. Injury treatment should involve a qualified healthcare provider.
The three mechanisms operate through independent signaling pathways — this independence means the combination is unlikely to produce receptor competition or pathway saturation.
The peptides
Why these work together
Tissue healing is a complex process involving multiple sequential and overlapping phases: hemostasis, inflammation, proliferation, and remodeling. This stack assigns a primary peptide to key bottlenecks across these phases.
In the inflammatory-to-proliferative transition, BPC-157's angiogenic effects ensure that new blood vessels form to supply the healing tissue with oxygen, nutrients, and immune cells. Its FAK-paxillin pathway activation promotes cell adhesion at the wound site and initiates the tissue remodeling cascade. Simultaneously, TB-500's actin upregulation accelerates the migration of fibroblasts, macrophages, and other repair cells to the injury, shortening the inflammatory phase and enabling the proliferative phase to begin sooner.
During the proliferative and remodeling phases, GHK-Cu takes a primary role. It activates matrix metalloproteinases (MMPs) that clear damaged extracellular matrix, making room for new tissue. It then stimulates the synthesis of collagen types I and III, elastin, and glycosaminoglycans — the structural components of properly organized tissue. This ECM remodeling step is critical for functional recovery, not just wound closure. Without proper ECM remodeling, healed tissue is weaker and more prone to re-injury.
The three mechanisms operate through independent signaling pathways: BPC-157 through FAK-paxillin and NO modulation, TB-500 through G-actin/F-actin dynamics, and GHK-Cu through copper-dependent enzymatic activation and gene expression modulation. This independence means the combination is unlikely to produce receptor competition or pathway saturation.
Suggested protocol
All three peptides at full therapeutic doses. BPC-157 injected near the injury for localized angiogenesis. TB-500 at loading dose for maximum cell migration. GHK-Cu injectable + topical for ECM remodeling.
BPC-157 continues at full dose. TB-500 reduces to maintenance frequency. GHK-Cu injectable moves to every other day while topical continues.
BPC-157 at reduced dose for continued support. TB-500 and GHK-Cu injectable discontinued. GHK-Cu topical can continue as needed with no safety concerns.
Safety considerations
Nausea, headache, injection site irritation. Angiogenic properties: caution with tumors. Under FDA reclassification review.
Lethargy, injection site reactions. Under FDA reclassification review. Banned by WADA.
Well-tolerated topically (decades of use). Injectable low-risk at standard doses. Minimal side effects reported.
The combination of all three peptides has never been studied in clinical trials. Additive side effects, drug interactions, and long-term safety are unknown. Not appropriate for individuals with active or prior pancreatitis, MEN 2 syndrome, active cancer, or during pregnancy/breastfeeding. Physician supervision is essential.
Frequently asked questions
The Wolverine stack (BPC-157 + TB-500) addresses angiogenesis and cell migration. This healing stack adds GHK-Cu, which specifically targets extracellular matrix remodeling — the process of clearing damaged tissue and building properly organized new tissue. The addition addresses a gap in the Wolverine stack: proper tissue architecture restoration, not just wound closure.
Yes. GHK-Cu's small molecular weight (340 Da) allows topical absorption through skin. For surface wounds, topical GHK-Cu serums applied directly to the wound are effective and have published human evidence. For deeper tissue injuries (tendons, ligaments, internal structures), subcutaneous injection near the injury site delivers GHK-Cu to tissues that topical products cannot reach. Both routes can be used simultaneously.
The healing stack is commonly discussed in post-surgical recovery contexts, and the individual peptides have preclinical evidence supporting accelerated tissue repair. However, no clinical trials have validated this use. Importantly, discuss any post-surgical supplement or peptide use with your surgeon — BPC-157's angiogenic effects could theoretically affect surgical site healing in unexpected ways, and timing relative to the surgery matters.
Anecdotal reports describe initial pain reduction and improved mobility within 1-2 weeks, with significant healing progress over 4-8 weeks depending on injury type and severity. GHK-Cu's ECM remodeling effects may take longer to manifest (4-8 weeks) as tissue architecture restoration is a slower process than initial wound closure. Complete recovery timelines depend on injury severity and concurrent physical rehabilitation.
Tendon injuries are one of the most commonly reported use cases for this stack. BPC-157 has the most preclinical evidence for tendon repair, including studies on transected Achilles tendons showing 72% accelerated healing. TB-500 supports tendon repair through cell migration. GHK-Cu's collagen synthesis stimulation is relevant because tendons are primarily composed of type I collagen. Physical therapy and load management remain essential alongside any peptide protocol.
Individual side effects are generally mild: nausea and headache (BPC-157), lethargy and injection site reactions (TB-500), and minimal side effects for GHK-Cu. The combination has not been studied, so additive effects are unknown. The main theoretical concern is BPC-157's angiogenic properties combined with GHK-Cu's tissue growth stimulation in the context of existing tumors. Monitor for unusual tissue growth, excessive scarring, or worsening symptoms and discontinue if any occur.